1. Home
  2. RPC vs SPRY Comparison

RPC vs SPRY Comparison

Compare RPC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ridgepost Capital Inc. Class A Common Stock

RPC

Ridgepost Capital Inc. Class A Common Stock

N/A

Current Price

$8.74

Market Cap

932.7M

Sector

Finance

ML Signal

N/A

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$8.68

Market Cap

823.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPC
SPRY
Founded
1992
2015
Country
United States
United States
Employees
267
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
932.7M
823.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RPC
SPRY
Price
$8.74
$8.68
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$11.00
$40.00
AVG Volume (30 Days)
510.2K
1.6M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
1.96%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$84,278,000.00
Revenue This Year
$16.82
$87.40
Revenue Next Year
$15.80
$81.64
P/E Ratio
$53.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.79
$6.66
52 Week High
$9.32
$18.63

Technical Indicators

Market Signals
Indicator
RPC
SPRY
Relative Strength Index (RSI) 70.48 53.70
Support Level $6.94 $8.61
Resistance Level N/A $9.46
Average True Range (ATR) 0.32 0.49
MACD 0.09 0.11
Stochastic Oscillator 89.78 53.39

Price Performance

Historical Comparison
RPC
SPRY

About RPC Ridgepost Capital Inc. Class A Common Stock

Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: